Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

3 years ago
R&D
Cell/Gene Tx

Who are the young bio­phar­ma lead­ers mak­ing their mark in the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

3 years ago
Editor's note

EQRx to trim more than 40 staffers in re­struc­tur­ing ma­neu­ver

3 years ago
People

Adding to Claudin18.2 port­fo­lio, As­traZeneca pays $63M cash for an­ti­body-drug con­ju­gate out of Chi­na

3 years ago
Deals

Fol­low­ing clin­i­cal hold lift, Astel­las posts ear­ly Pompe gene ther­a­py da­ta

3 years ago
R&D
Cell/Gene Tx

Graphite Bio gives up on lead sick­le cell pro­gram, halves staff in wake of safe­ty scare

3 years ago
People
R&D

For­mer high-fly­ing I/O biotech shelves lead drugs, chops staff and hands off the rem­nants in Nas­daq reshuf­fle

3 years ago
Deals
Bioregnum

Cap­si­da and Ab­b­Vie make $70M up­front deal for ge­net­ic med­i­cines in eye dis­eases

3 years ago
Deals
Pharma

J&J to im­pose new lim­its on 340B ac­cess af­ter in­dus­try court win

3 years ago
Pharma

Pfiz­er says RSV shot to pro­tect in­fants may be avail­able by 2023-24 cold and flu sea­son

3 years ago
Pharma
FDA+

Boehringer In­gel­heim broad­casts third pod­cast sea­son around rare lung con­di­tion

3 years ago
Pharma
Marketing

Charles Riv­er hand­ed sub­poe­na by DOJ over non-hu­man pri­mate sup­ply

3 years ago
Pharma
Manufacturing

Gener­ic drug­mak­er Ako­rn shut­ters Illi­nois plant, lays off 400 em­ploy­ees

3 years ago
Manufacturing

UK ini­ti­ates re­view of clin­i­cal tri­als af­ter de­creas­es in re­cruit­ment, num­ber of stud­ies

3 years ago
Pharma

CMS to work close­ly with FDA on ac­cel­er­at­ed ap­proval pay­ment re­forms

3 years ago
FDA+
Law

Phar­maEssen­tia takes Besre­mi rare blood can­cer mes­sage to con­sumers

3 years ago
Pharma
Marketing

Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

3 years ago
People
R&D

Pfiz­er, Bay­er lay off staff in Cal­i­for­nia; Mod­er­na signs gene edit­ing deal with David Hal­lal biotech

3 years ago
News Briefing

Apel­lis jumps on the cash train af­ter FDA ap­proves its GA drug

3 years ago
Financing

Ru­bius fails to find al­ter­na­tive as board ap­proves dis­so­lu­tion

3 years ago
People

An­oth­er BioCryst Fac­tor D in­hibitor hits clin­i­cal de­lay two months af­ter first one dis­con­tin­ued

3 years ago
R&D

Vivek Ra­maswamy launch­es bid for US pres­i­den­cy, re­signs from Roivant board

3 years ago
People

Kin­nate en­gi­neers $24M deal to win con­trol of Chi­na joint ven­ture back from Or­biMed, Fore­site

3 years ago
Deals
China

Tan­gled in bank­rupt­cy pro­ceed­ings and le­gal tus­sle, Sor­ren­to se­cures $75M to stay afloat

3 years ago
Financing
First page Previous page 372373374375376377378 Next page Last page
A service from the Financial Times